Drug Trial Radar · NCT04383925
Trial to Compare Two Strains of BCG
Last checked: Nov 19, 2026Latest source record: Jan 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16,390
Actual
Start
May 4, 2020
Primary completion
Oct 30, 2022
Study completion Dec 1, 2022
Sponsor
- Lead sponsor
- Bandim Health ProjectAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Southern Denmark
- First posted
- May 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (care provider, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 days, up to 42 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The trial will be a two-year outcome assessor-blinded RCT at the maternity ward of hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare BCG-Japan versus BCG-Russia 1:1 in 15,000 infants with respect to mortality, morbidity and case-fatality rate during hospital admission. The trial will also examine the association between BCG strains and BCG skin reaction characteristics by six weeks (data collected by telephone) and at two and six months (data collected at home-visits to a subgroup of the cohort). As a secondary aim, this large study will be used to further evaluate the role of maternal BCG immune priming for overall health, since there are indications that maternal BCG scarring enhances the non-specific effects of BCG.
Conditions
- Death, Infant
- Morbidity;Infant
Interventions
BCG-JapanBiological
Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
BCG-RussiaBiological
Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of all-cause mortality overall and stratified by maternal BCG scar status and sexTime frame: Six weeks of age
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bandim Health Project
Bissau, Guinea-Bissau
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.